Clifford Chance advises on the sale of Inke to Keensight Capital

Clifford Chance has advised Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders on the sale of Spanish pharmaceutical company Inke to private equity firm Keensight Capital, a leading private equity fund which focuses on pan-European Growth Buyout investments.

The firm cross-border multidisciplinary team advising Neuraxpharm was led by M&A Private Equity partners Samir Azzouzi from the Madrid office, supported by senior associate Daniel García Juárez and associates Andreína Velásquez, Sofía Albiñana and Juan Valcárcel, from the M&A Private Equity practice in Madrid.

Partner André Duminy and senior associate Claudia Hall, from the London office, also assisted on the transaction. And Jörg Rhiel (partner) from the Frankfurt office, also advise on the transaction.

Established in 1980 and based in Castellbisbal, near Barcelona (Spain), Inke combines over 20 years of in-house experience in micronization and particle engineering with complex synthesis processes and high regulatory expertise. It has established preferential relationships with major pharmaceutical companies worldwide, including in key markets such as the US and the EU, as well as the highly regulated Japanese market.

The firm previously advised Permira on its acquisition of Neuraxpharm in 2020.

Julia Gil